Allergy plays a significant role in patients with atopic dermatitis. The disease mostly flares up when the patient is around the things that cause allergic reactions. It is particularly common in infants and children, who are estimated to be about 10-20% having eczema, as mentioned under the American College of Allergy, Asthma & Immunology. There is a growing number of foundations, which are raising awareness regarding eczema and different types of dermatitis across various regions. The developed regions have a higher prevalence, as well as population, which is more active toward early detection of chronic autoimmune diseases. Thus, the role of rising campaigns each year is very important to fuel the growth of atopic dermatitis market. In March 2017, Sanofi and Regeneron Pharmaceuticals, Inc. announced US FDA approval of Dupixent (dupilumab) Injection. Following the approval, Dupixent was launched as a pre-filled syringe, which can be self- administered as a subcutaneous injection every other week after an initial loading dose. The high potency, long-lasting effect, and ease of administration have made Dupixent one of the most preferred form of Atopic dermatitis treatment method, however, the high annual cost of USD 37,000 can limit the adoption rates.

1. INTRODUCTION 

2. RESEARCH METHODOLOGY

3. EXECUTIVE SUMMARY 

4. MARKET DYNAMICS 

5. MARKET SEGMENTATION 

6. COMPETITIVE LANDSCAPE 

7. MARKET OPPORTUNITIES AND FUTURE TRENDS